Spyre Therapeutics, Inc. (SYRE) FY2025 10-K Annual Report
Spyre Therapeutics, Inc. (SYRE) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 19, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Spyre Therapeutics, Inc. FY2025 10-K Analysis
Business Overview
- • Core business model redesigned as clinical stage biotech focused on next-generation monoclonal antibodies for IBD and immune-mediated diseases
- • Emphasis on half-life extended antibodies aiming for less frequent, self-administered subcutaneous injections
Management Discussion & Analysis
- • No revenue reported in FY 2026, focus on pre-clinical stage asset acquisition and licensing
- • No profitability or margin data provided due to early-stage operations and recent acquisitions
Risk Factors
- • Legal risk from increased costs to comply with Nasdaq listing rules and SEC requirements post going public
- • Macroeconomic impact of $2.0M lease termination fee for Austin office abandonment creating liquidity pressure
Spyre Therapeutics, Inc. FY2025 Key Financial MetricsXBRL
Revenue
$0
Net Income
-$155M
▲ +25.4% YoY
ROE
-21.7%
▲ +1847bp YoY
Total Assets
$778M
▲ +27.8% YoY
Operating Cash Flow
-$169M
▼ -7.5% YoY
Source: XBRL data from Spyre Therapeutics, Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Spyre Therapeutics, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.